Publikationen

Berg P, Bakker C, Sander M, Hasselblad Lundstrøm N, Erneholm K, Tshinanu FM, Kholmanshikh O, van Nuffel F, Müller S, Ruppert-Seipp G, Maurer GD, Januskiene J, Mantziri M, Mulder B, van Nimwegen FA, Vasilcanu D, Wändel Liminga U (2025): Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases.
Gene Ther Dec 22 [Epub ahead of print].
Text

Berg P, Ruppert-Seipp G, Müller S, Maurer GD, Hartmann J, Holtick U, Buchholz CJ, Funk MB (2025): CAR T-cell-associated secondary malignancies challenge current pharmacovigilance concepts.
EMBO Mol Med 17: 211-218.
Text

Berg P, Schönefeld S, Ruppert-Seipp G, Funk MB (2022): Regulatory Measures to Improve the Safety of CAR-T-Cell Treatment.
Transfus Med Hemother 50: 218-225.
Text

Funk MB, Frech M, Spranger R, Keller-Stanislawski B (2015): Überwachung der Sicherheit von Zelltherapeutika (CBMPs).
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 58: 1239-1246.
Online-Abstract